BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

BioTech Health X

803 posts

Biotech NewsArdelyx (ARDX) Tops Q3 With $110.33M Revenue

  • BioTech Health X
  • December 7, 2025
Ardelyx Inc. (NASDAQ:ARDX) is a commercial-stage biopharmaceutical company focused on developing and delivering first-in-class medicines for patients suffering…
0 Shares
0
0
0
0
0
0
0

Biotech NewsKymera Therapeutics (KYMR) Jumps 10.2% in a Month—Is Wall Street Pricing in a Major 2026 Breakout?

  • BioTech Health X
  • December 6, 2025
Kymera Therapeutics Inc. (NASDAQ:KYMR), a publicly traded biotechnology company, was founded to pioneer the rapidly expanding field of…
0 Shares
0
0
0
0
0
0
0

Biotech NewsBiodexa Pharmaceuticals (BDRX) Launches Phase 3 Trial for eRapa — Can This $2.81M Biotech Transform FAP Treatment?

  • BioTech Health X
  • December 6, 2025
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for diseases with significant…
0 Shares
0
0
0
0
0
0
0

Biotech NewsGalectin Therapeutics (GALT) Surges 10.5% After Insider Sells 120,000 Shares

  • BioTech Health X
  • December 6, 2025
Galectin Therapeutics Inc. (NASDAQ:GALT) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for fibrotic disease, cancer,…
0 Shares
0
0
0
0
0
0
0

Biotech NewsAnalysts Boost Target to $24 as Ocular Therapeutix (OCUL) Nears Major Catalyst

  • BioTech Health X
  • December 6, 2025
Ocular Therapeutix, Inc. is a biotechnology company dedicated to transforming the treatment landscape for serious ocular diseases through…
0 Shares
0
0
0
0
0
0
0

Biotech NewsEnveric Biosciences (ENVB) Reports Breakthrough PTSD Results as EB-003 Moves Toward IND in 2026

  • BioTech Health X
  • December 5, 2025
Enveric Biosciences Inc (NASDAQ:ENVB) is a biotechnology company built on a scientific foundation of developing next-generation neuroplastogenic therapeutics…
0 Shares
0
0
0
0
0
0
0

Biotech NewsSensei Biotherapeutics (SNSE) Cuts Workforce by 65% as It Prepares for a Potential Sale—Is a Major Buyout Coming?

  • BioTech Health X
  • December 5, 2025
Sensei Biotherapeutics Inc (NASDAQ:SNSE) is a clinical stage biotechnology company built on a foundation of innovative cancer research…
0 Shares
0
0
0
0
0
0
0

Biotech NewsViking Therapeutics (VKTX) Surges After 78% of Patients Achieve Normal Glycemic Control in Obesity Trial

  • BioTech Health X
  • December 5, 2025
Viking Therapeutics Inc. (NASDAQ:VKTX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for metabolic disorders, obesity,…
0 Shares
0
0
0
0
0
0
0

Biotech NewsBiodexa Pharmaceuticals (BDRX) Launches Phase 3 Trial for eRapa — Can This $2.8M Biotech Deliver a Breakthrough?

  • BioTech Health X
  • December 5, 2025
Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) is a clinical-stage biopharmaceutical company operating within the biotechnology industry and focused on discovering,…
0 Shares
0
0
0
0
0
0
0

Biotech NewsWest Pharmaceutical Services (WST) Could Outperform as Analysts Project $350.77 Price Target

  • BioTech Health X
  • December 2, 2025
West Pharmaceutical Services Inc. (NYSE:WST) is one of the most established and influential companies in the global pharmaceutical…
0 Shares
0
0
0
0
0
0
0

Biotech NewsDon’t Let the 70.7% YTD Jump Fool You—Axsome Therapeutics (AXSM) Still Faces Massive Downside Risk

  • BioTech Health X
  • December 2, 2025
Axsome Therapeutics (NASDAQ:AXSM) is a clinical-stage biopharmaceutical company that has grown into one of the most closely watched…
0 Shares
0
0
0
0
0
0
0

Biotech NewsTG Therapeutics (TGTX) Reports Explosive Q3 Revenue Surge to $161.7M as BRIUMVI Dominates MS Market

  • BioTech Health X
  • December 2, 2025
TG Therapeutics Inc. (NASDAQ:TGTX) is a biopharmaceutical company built on a vision to transform the treatment landscape for…
0 Shares
0
0
0
0
0
0
0

Biotech NewsAbbott Laboratories (ABT) Posts Stunning 21% EPS Growth—Is This the Strongest Healthcare Stock of 2025?

  • BioTech Health X
  • December 2, 2025
Abbott Laboratories(NYSE:ABT) is one of the most established and influential healthcare companies in the world, with a history…
0 Shares
0
0
0
0
0
0
0

Biotech NewsFennec Pharmaceuticals (FENC) Reveals Stunning Japan Trial Data—Hearing Loss Drops from 63% to Just 24%

  • BioTech Health X
  • December 2, 2025
Fennec Pharmaceuticals (NASDAQ:FENC) is a specialty pharmaceutical company built on the mission of addressing one of the most…
0 Shares
0
0
0
0
0
0
0

Biotech NewsJANUX Therapeutics Just Hit Its Lowest Price Since 2024 — Here’s Why Wall Street Is Still Bullish

  • BioTech Health X
  • December 2, 2025
Janux Therapeutics is a clinical-stage biotechnology company built on the vision of transforming cancer treatment through next-generation, tumor-activated…
0 Shares
0
0
0
0
0
0
0

Biotech NewsAcadia Healthcare (ACHC) Faces 168% Spike in Claims — Investors Ask: Panic or Massive Buying Opportunity?

  • BioTech Health X
  • December 2, 2025
Acadia Healthcare Company has grown into one of the largest and most influential behavioral health systems in the…
0 Shares
0
0
0
0
0
0
0

Biotech NewsAstera Labs (ALAB) Surges as New NVLink Fusion Breakthrough Redefines AI Infrastructure

  • BioTech Health X
  • December 2, 2025
Astera Labs (NASDAQ:ALAB) was founded with a singular vision: to solve one of the most fundamental bottlenecks in…
0 Shares
0
0
0
0
0
0
0

Biotech NewsCVS Health (CVS) Skyrockets 27% in 6 Months as MBR Hits 92.8%

  • BioTech Health X
  • November 30, 2025
CVS Health Corporation (NYSE:CVS) has evolved into one of the most influential and vertically integrated healthcare companies in…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • PMV Pharmaceuticals (PMVP) Forecast 2026: One Mutation, One Oral Drug, and a Re-Rating That Could Hit Fast
  • Oncolytics (ONCY) Is a $90M “Science vs. Reality” Fight—And 2026 Is When Pelareorep Has to Win
  • Nkarta (NKTX)’s Plot Twist: From Cancer Chaos to Autoimmune “Immune Reset” Hype
  • Context (CNTX)’s Glow-Up: From “Old Thesis” to T-Cell Engager Chaos (In a Good Way)
  • The $290M Cancer Biotech With Phase 3 “Proof”: Candel (CADL)’s Viral Immunotherapy Isn’t Just a Science Fair Anymore
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • February 13, 2026
    PMV Pharmaceuticals (PMVP) Forecast 2026: One Mutation, One Oral Drug, and a Re-Rating That Could Hit Fast
    • February 13, 2026
    Oncolytics (ONCY) Is a $90M “Science vs. Reality” Fight—And 2026 Is When Pelareorep Has to Win
    • February 13, 2026
    Nkarta (NKTX)’s Plot Twist: From Cancer Chaos to Autoimmune “Immune Reset” Hype
    • February 13, 2026
    Context (CNTX)’s Glow-Up: From “Old Thesis” to T-Cell Engager Chaos (In a Good Way)
    • February 13, 2026
    The $290M Cancer Biotech With Phase 3 “Proof”: Candel (CADL)’s Viral Immunotherapy Isn’t Just a Science Fair Anymore
Recent Posts
  • Verastem (VSTM) Isn’t “Small-Cap Roulette” Anymore—It’s a Commercial Oncology Ramp With a 2026 Twist
    • February 13, 2026
  • The Market Cap Is Small, the Idea Is Huge: Can Allogene (ALLO) Make CAR-T as Easy as Ordering a Drug?
    • February 13, 2026
  • 44% Real-World Response? Iovance (IOVA) Just Made “Off-the-Bench” Data the New Headline
    • February 13, 2026
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (5)
  • Biotech News (787)
  • Uncategorized (2)
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top